Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erin Lovewell

Nurse Practitioner, Family Mission, KS Nurse Practitioner

NPI 1942452560 CMS profile 10859575

5555 W 58Th St, Mission, KS 66202

Open in the dashboard

General payments

$7,432

487 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Lovewell of Mission, KS is reported in the CMS Open Payments database as having received $7,432 across 487 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,854 123
2024 General $2,126 137
2023 General $1,561 102
2022 General $1,230 77
2021 General $662 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Lovewell
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Erin Lovewell were reported at $1,854. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Erin Lovewell Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $662 $124 $35–$379 $132
2022 $1,230 $141 $44–$430 $149
2023 $1,561 $154 $49–$476 $160
2024 $2,126 $165 $51–$504 $164
2025 $1,854 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,201 142 payments
  2. Lilly USA, LLC $707 43 payments
  3. Pfizer Inc. $603 71 payments
  4. Novo Nordisk Inc $594 38 payments
  5. AstraZeneca Pharmaceuticals LP $543 26 payments
  6. Amgen Inc. $248 18 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $192 11 payments
  8. Abbott Laboratories $182 9 payments
  9. Shield Therapeutics Inc $146 6 payments
  10. Kowa Pharmaceuticals America, Inc. $142 9 payments
  11. Other $1,876 114 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,407 486 payments
  2. Education $25 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $1,112 74 payments
  2. QULIPTA $709 38 payments
  3. VRAYLAR $583 34 payments
  4. NURTEC ODT $533 65 payments
  5. Ozempic $431 27 payments
  6. MOUNJARO $426 25 payments
  7. RYBELSUS $386 24 payments
  8. ZEPBOUND $370 23 payments
  9. AIRSUPRA $355 16 payments
  10. FARXIGA $290 9 payments
  11. Other $4,703 297 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

2,635

Median for Nurse Practitioner: 389

Drug cost

$253,681

Median for Nurse Practitioner: $21,885

Branded share of claims

16.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 62 $65,305
Ozempic Semaglutide Brand 35 $45,964
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 43 $33,026
Trulicity Dulaglutide Brand 21 $30,412
Gemtesa Vibegron Brand 23 $19,149
Farxiga Dapagliflozin Propanediol Brand 13 $15,737
Eliquis Apixaban Brand 16 $11,079
Tresiba Flextouch U-200 Insulin Degludec Brand 13 $7,817
Synthroid Levothyroxine Sodium Brand 17 $2,055
Atorvastatin Calcium Generic 256 $1,750

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$25,793

Of which drugs: $5,660

Medicare patients

140

Average age 75

Services billed

4,186

109 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 51%
Depression 34%
Osteoporosis 23%
Diabetes 22%
Chronic kidney disease 18%
Atrial fibrillation 16%
Ischemic heart disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 15 15 $2,195
Vaccine for influenza for injection into muscle 90662 Office 17 17 $1,381

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $234
$234 — —
UBRELVY
  • AbbVie, Inc. $217
$217 — —
NURTEC ODT
  • PFIZER INC. $169
$169 — —
QULIPTA
  • AbbVie, Inc. $136
$136 — —
ZEPBOUND
  • Lilly USA, LLC $129
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

487 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record